WUH: 07480-Randomized trial of COBRA PzF Stenting To Reduce Duration of Triple Therapy (COBRA-REDUCE)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Symptomatic Ischemic
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Subjects must be older than 18 years old
- Subjects must have schemic symptoms (stable or unstable angina or NSTEMI without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia
- Subjects must be receiving oral anticoagulation with coumadin derivatives or non –vitamin K oral anticoagulants
- Subjects must complete and sign the written, informed consent
You may not be eligible for this study if the following are true:
-
- Subjects with cardiogenic shock
- Subjects with target lesion located in left main trunk
- Subjects have bifurcation interventions with a planned 2 –stent strategy
- Subjects with vessel size too small for implantation of a 2.5 mm stent by visual estimation
- Subjects requiring staging PCI procedure within 6 months after the index procedure
- Subjects requiring DAPT for more than 2 weeks after the index procedure
- Subjects with malignancies or other co –morbid conditions with life expectancy less than 12 months or that may result in protocol non –compliance
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.